About Octreotide LAR Inj 20mg/30mg
Octreotide provides effective, controlled and extended release and hence sustained hormone regulation with less frequent dosing. It is the leading treatment for acromegaly, neuroendocrine tumors, and severe diarrhea associated with carcinoid syndrome, thanks to its targeted suppression of excessive hormone secretion. It also promises a strong safety profile.
Packaging: Ampoules, Multi-Dose Vials
Storage: 2-8 (36-46)
Strength: 30 mg / 20 mg
Dosage: 20 mg Intramuscular Once Every 4 Weeks for 3 Months or 30 mg Every 4 Weeks
Precision Dosage for Effective TherapyAvailable in 20mg and 30mg strengths, Octreotide LAR is tailored to individual therapeutic needs for managing growth hormone disorders and tumors. Its long-acting formula allows for monthly dosing, improving patient compliance and convenience.
Simple Reconstitution and AdministrationEach vial comes with a solvent for reconstitution, ensuring quick preparation of a uniform suspension prior to intramuscular injection. Administration should be performed only by qualified medical staff following prescription instructions.
Quality Assured and Secure StorageComplying with GMP manufacturing standards, every batch is tested for purity and consistency. Store refrigerated at 2C to 8C and avoid freezing. The lyophilized formula's shelf life is 24 months, offering reliability for stock management.
FAQ's of Octreotide LAR Inj 20mg/30mg:
Q: How should Octreotide LAR Inj 20mg/30mg be prepared before administration?
A: The powder must be reconstituted with the supplied solvent to form a suspension before intramuscular injection. Reconstitution should be handled by a healthcare professional to ensure proper preparation and dosing.
Q: What are the main therapeutic indications for this medication?
A: Octreotide LAR is primarily prescribed for the treatment of acromegaly, certain carcinoid tumors, and VIPomas, as a long-acting somatostatin analogue therapy.
Q: When and how often is Octreotide LAR administered?
A: The injection is typically administered once monthly, as directed by a physician. Adherence to the dosing schedule is crucial to maintain stable drug levels and optimized therapeutic outcomes.
Q: Where should the medication be stored before use?
A: The product must be stored in a refrigerator at a temperature between 2C and 8C. It should not be frozen and must remain in its original packaging until reconstitution.
Q: What are the benefits of the long-acting release formulation?
A: The long-acting release allows for once-monthly administration, reducing injection frequency, supporting better patient compliance, and ensuring sustained medication levels.
Q: What quality and safety standards does this product adhere to?
A: Octreotide LAR is manufactured in compliance with Good Manufacturing Practice (GMP) standards, ensuring consistent quality, safety, and efficacy in every vial.